P ositron emission tomography (PET) ligands for tau have the potential to improve diagnostic accuracy and allow reliable in vivo quantification of brain tau burden in Alzheimer's disease (AD) and related tauopathies. [1] [2] [3] [4] 
[F-
18]-AV-1451 (or T807) was developed to detect tau in the form of paired helical filaments (PHFs). 5 Recent studies
show that patients with mild cognitive impairment (MCI) and AD dementia exhibit significantly higher [F-18]-AV-1451-PET retention than cognitively normal controls. [6] [7] [8] [9] [10] [11] [12] Importantly, [F-18] -AV-1451-PET patterns correlate with disease severity and seem to match the predicted topographic Braak staging 13 of neurofibrillary tangles (NFTs) in AD. 6, 12, 14, 15 Moreover, [F-18]-AV-1451-PET retention correlates with increased tau and decreased Ab 42 in cerebrospinal fluid in AD patients and normal controls. 7, 10, 16 All these data suggest that [F-18] -AV-1451 is a promising biomarker for in vivo detection of tau lesions in AD.
Its usefulness as a biomarker in non-Alzheimer tauopathies, however, remains controversial. Some studies report increased [F-18] -AV-1451-PET retention in patients clinically diagnosed with progressive supranuclear palsy (PSP) [17] [18] [19] and chronic traumatic encephalopathy (CTE), 20, 21 whereas others notice PET patterns that cannot be reliably distinguished from controls. 22 These discrepancies highlight the need for neuroimagingpathological studies conducted on postmortem material from individuals imaged while alive.
We recently conducted an analysis of [F-18]-AV-1451 autoradiographic and in vitro binding patterns in legacy postmortem brain samples representing a broad spectrum of neurodegenerative pathologies. 23 Our observations suggested that [F-18]-AV-1451 exhibits high binding affinity to tau lesions in AD, but low affinity for tau inclusions in nonAlzheimer tauopathies. Importantly, we observed robust offtarget binding to neuromelanin-and melanin-containing cells that should be carefully taken into account when interpreting [F-18]-AV-1451-PET patterns. 23 Other authors have made similar observations. 24, 25 Here, we expand the characterization of this tracer by examining the correlation between in vivo antemortem and postmortem [F-18] -AV-1451 binding patterns in three autopsy-confirmed non-Alzheimer tauopathy cases (two PSP 26 cases and a MAPT P301L mutation 27, 28 carrier). Our results suggest that [F-18]-AV-1541 holds great promise as a surrogate marker for detection of tau pathology in AD, but exhibits low affinity for tau aggregates in these non-Alzheimer tauopathy cases.
Subjects and Methods
The study was approved by the local Institutional Review Board. Informed consent for neuroimaging and brain autopsy was obtained for each subject. 
In Vivo [F-18]-AV-1451 PET Imaging

Brain Tissue Samples
Brains were cut at time of removal on standard anatomical landmarks and areas of interest were identified and frozen at -80 8C. Tissue blocks were fixed in formalin for 1 week before being embedded in paraffin and cut at 8 lm. Diagnostic histological evaluation was performed on 19 regions representative for a spectrum of neurodegenerative diseases and in accord with published guidelines. [34] [35] [36] 
SDD-AGE
SDD-AGE was carried out as previously described, with slight modifications. 37, 38 First, 250mg of frozen tissue containing each ROI was homogenized in cold PBS with Protease Inhibitor Cocktail (13; Roche, Indianapolis, IN). Homogenates were spun at 3,000g for 5 minutes at 4 8C and supernatant was collected. Next, 1.5% agarose gel was prepared by dissolving agarose in Buffer G (20mM of Tris-Base, 200mM of glycine) and adding 10% sodium dodecyl sulfate (SDS) to a final concentration of 0.02%. Then, 60 lg of lysate protein was incubated with 0.02% SDS sample buffer for 7 minutes at RT before loading. SDD-AGE was run in Laemmli buffer (Buffer G with 0.1% SDS) at 35V for 16 hours at 4 8C. Protein was transferred via capillary action using 20 pieces of thick Whatman (GB 005) and eight pieces of medium Whatman (GB 003) to Immobilon polyvinylidene flouride membrane (Millipore, Billerica, MA) at 4 8C for 16 to 24 hours. Membranes were blocked in 5% nonfat dry milk (NFDM) in 1 3 Tris-buffered saline-Tween (TBS-T) for 1 hour and probed for total tau (rabbit antibody, 1:4,000; Dako, Carpinteria, CA) and for PHF-tau (mouse PHF-1 antibody, 1:4,000) overnight at 4 8C. Membranes were washed five times with TBS-T, probed with goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (1:2,000; Bio-Rad Laboratories, Hercules, CA) or goat anti-mouse HRP (1:2,000), respectively, for 1 hour in 5% NFDM in TBS-T at RT, and washed five times with TBS-T. Membranes were developed using Enhanced Chemiluminescence (ECL) Substrate (Pierce, Appleton, WI) for 1 minute and exposed to film (GE Healthcare, Little Chalfont, UK). Images were quantified using ImageJ software (National Institute of Health).
Results
Clinical Case Description SUBJECT 1. Subject 1 was a 77-year-old male with a 7-year history of progressive speech and cognitive symptoms. He was clinically diagnosed with agrammatic/nonfluent variant of primary progressive aphasia. 39 He subsequently developed dysphagia, gait instability and falls, hand tremor, right upper extremity rigidity, and limited vertical eye movements, fulfilling clinical criteria for PSP. 40 [F-18]-AV-1451-PET scan was performed 19 months predeath; at that time, he was mildly demented. His motor phenotype worsened further over time.
SUBJECT 2. Subject 2 was a 68-year-old male with a 7-year history of progressive hand tremor and gait instability. He developed repeated falls, dysarthria, dysphagia, diplopia with limitation of vertical eye movements, and dysautonomic symptoms, meeting clinical criteria for probable PSP. 40 [F-18]-AV-1451-PET scan was performed 5 months predeath. At that time, he was wheelchair bound and mildly demented.
SUBJECT 3. Subject 3 was a 56-year-old male with a 3-year history of progressive cognitive and behavioral symptoms. He was clinically diagnosed with behavioral variant frontotemporal dementia. 41 His family history was consistent with an autosomal-dominant pattern. Genetic testing confirmed the MAPT P301L
PET images from the three study subjects (A-C). PET images from a cognitively normal 85-yo male (D) and a 78-yo male clinically diagnosed with mild AD (E), using the same color scaling (SUVR values ranging from 1 to 2), are shown for comparison. The three study subjects exhibited increased [F-18]-AV-1451 in vivo retention, predominantly in basal ganglia and midbrain (subject 1 PSP (A), subject 2 PSP (B), and subject 3 MAPT P301L mutation carrier (C)). Elevated uptake in basal ganglia and midbrain, and some lower retention in the medial and inferior temporal regions, was also observed in the 85-yo cognitively normal control (D). PET imaging from a 78-yo male clinically diagnosed with AD showed the typical in vivo AV-1451 distribution pattern of AD described in Johnson et al, 6 with high retention in the inferior/lateral temporal, parietal, occipital, and precuneus/posterior cingulate regions (E). Abbreviations: AD 5 Alzheimer dementia; CTL 5 control subjects; MAPT 5 microtubule-associated protein tau; PET 5 positron emission tomography; PSP 5 Progressive Supranuclear Palsy; yo 5 years old; SUVR 5 standardized uptake value ratio. In Vivo [F-18]-AV-1451-PET Imaging PET images from the three subjects are shown in Figure  1A -C. Images from a cognitively normal individual and a mild AD patient are shown for comparison (Fig 1D-E) . Subject 1's PET scan showed elevated retention predominantly in basal ganglia and midbrain, and lower signal in frontal and temporal cortices, white matter (left-lateralized), and cerebellar dentate nuclei (right-lateralized). Subject 2's PET scan showed elevated retention most prominent in basal ganglia and midbrain, and lower signal in medial and lateral prefrontal and anterior temporal cortices, white matter (right-lateralized), and cerebellar dentate nuclei (left-lateralized). Subject 3's PET scan showed elevated retention predominantly in basal ganglia and midbrain, and lower signal in prefrontal, temporal and parietal cortices and white matter (Fig 1A-C) . Overall, tracer retention in these cases was much lower than that observed in AD patients. 6, 11, 16 Neuropathological Examination Subject 1 showed the expected neuropathological lesions of PSP with tau-immunoreactive inclusions in neurons and glia in cerebral cortex, white matter, and other gray matter regions, including pallidum, midbrain, basis pontis, and cerebellar dentate nucleus. Neurofibrillary tangles (NFTs) were observed in entorhinal cortex (EC) and subiculum, consistent with age-related NFT Braak stage II. 13 In subject 2, histopathological exam revealed abundant tau-immunoreactive inclusions, mainly glial, in the form of tufted astrocytes, coiled bodies, and interfascicular threads. Their distribution included brainstem, cerebellum, thalamus, pallidum, limbic regions, and neocortex, consistent with the diagnosis of definite PSP. 42 Incidental agerelated NFTs were found in the EC and the CA1 hippocampal subfield. Subject 3 demonstrated an unusual histopathological phenotype in the setting of the MAPT P301L mutation. Rather than the expected presence of NFTs and neuritic processes, abundant small grain-like tau inclusions were present in cortex and white matter, with the heaviest burden in basal ganglia, resembling a MAPT S305I mutation carrier phenotype previously reported. 43 Scattered age-related NFTs in the EC, sparse diffuse Ab-plaques in the EC and temporal cortices, and rare temporal lobe TDP-43 inclusions were also detected.
[F-18]-AV-1451 Phosphor Screen and Nuclear Emulsion Autoradiography Phosphor screen autoradiography, using [F-18]-AV-1451 aliquots from material prepared for routine in vivo imaging on the same day, showed nearly identical binding patterns in the three cases (Fig 2A,C,E (Fig 1A-C) .
To confirm these observations and obtain cellular resolution, we dipped adjacent sections in a photographic nuclear emulsion, followed by IHC with appropriate tau antibodies. In agreement with our previous observations, 23 tangle-containing sections from AD exhibited strong concentration of silver grains matching the distribution of PHF-tau aggregates (data not shown) whereas brain slices from the three non-Alzheimer tauopathy cases showed no detectable silver grain accumulation ( Fig  2B,D,F) .
In Vitro [H-3]-AV-1451 Binding Assays
In vitro [H-3]-AV-1451 binding assays conducted in brain homogenates derived from the same tissue material used in autoradiography revealed no significant correlation between regional [F-18]-AV-1451-PET retention and in vitro tracer binding in any of the three cases (Fig 3) . Of note, with the exception of basal ganglia, some of the regions that exhibited high in vitro binding (eg, superior temporal, anterior cingulate, and superior frontal) showed very low [F-18]-AV-1451-PET signal (Fig 3) .
Tau Burden Quantification
Quantification of tau burden in immunostained sections (Fig 4A) revealed robust loads of tau lesions in multiple ROIs analyzed. However, no significant correlation could be detected between [F-18]-AV-1451-PET retention and postmortem tau burden in matching ROIs in any of the three cases (Fig 4B) .
Measurement of Tau Levels by SSD-AGE
SDD-AGE revealed the presence of tau in the form of low-molecular-weight (LMW) and high-molecular-weight (HMW) species. Representative SSD-AGE images are shown in Figure 5A (subject 1), Figure 5C (subject 2), and Figure 5E (subject 3). As expected, levels of total tau and phosphorylated tau were substantially lower in the non-Alzheimer tauopathy cases in comparison to AD. In subjects 1 and 3, no significant correlation was detected between tau levels and [F-18]-AV-1451-PET retention in matching ROIs (Fig 5B,F) . In subject 2, a statistically significant correlation was noticed between total-tau (HMW) and phospho-tau (LMW and HMW) levels and regional Fig 5D) . Of note, this significance was driven by the basal ganglia, and the correlation was lost when excluding this region from the analysis.
Discussion
We have carefully examined the correlation of in vivo and postmortem regional-and substrate-specific binding
Representative images from phosphor screen (A,C,E) and nuclear emulsion autoradiography (B,D,F) of brain slices from the three study subjects. The three cases showed a similar autoradiographic pattern with nondetectable AV-1451 binding across multiple brain ROIs known to contain high burden of tau pathology, including the basal ganglia, a region that exhibited elevated in vivo retention. Only two regions in these brains exhibited a strong autoradiographic signal, the EC (asterisk; reflecting age-related tangle pathology that served as internal positive control for our autoradiographic experiments), and midbrain sections containing the substantia nigra (asterisk; reflecting tracer off-target binding) (A,C,E). In both regions, [F-18]-AV-1451 binding was almost completely blocked after incubating the slides with 1 lM of unlabeled AV-1451. Microscopic images from slices dipped in the nuclear emulsion and immunostained with mouse PHF-1 antibody (a kind gift of Dr Peter Davies) showed negligible silver grain deposition colocalizing with PSP tau inclusions and tau grains in the MAPT P301L mutation carrier (B,D,F). As expected, neuromelanin-containing neurons of the substantia nigra were strongly labeled by silver grains (D,F). [F-18]-AV-1451 came out of compound library screens that used NFT-containing sections from AD brains. 5 Thus, it is not completely surprising that this tracer preferentially binds to tau filaments that compose NFTs and dystrophic neurites in AD, and medial temporal lobe age-related NFTs, but it exhibits low affinity for tau inclusions in non-Alzheimer tauopathies, such as Pick's disease, PSP or corticobasal degeneration (CBD), or to b-amyloid, a-synuclein, or TDP-43 deposits, as recently reported by us and others. [23] [24] [25] It is possible that tau conformation, composition and/or post-translational modifications are critical for [F-18]-AV-1451 binding. Of note, tau lesions in AD contain all six human tau isoforms, including three and four repeat isoforms (3R and 4R), and adopt the twisted ribbon structure of PHF. 44 The same is the case of tau filaments that form as a function of age and of a number of other tauopathies, including some MAPT mutations (like V337M 45 and R406W 46 ). However, in tauopathies like Pick's disease, PSP, CBD, or other MAPT mutations (like P301L), tau aggregates exist as straight filaments with either predominantly 3R or 4R isoforms. [26] [27] [28] 35, 47 Recent [F-18]-AV-1451 PET imaging studies consistently show significantly higher tracer retention in patients with MCI and AD dementia compared to controls. [6] [7] [8] [9] [10] [11] [12] Emerging PET data in non-Alzheimer tauopathies, however, provide conflicting results. Some studies report elevated [F-18]-AV-1451-PET retention, predominantly in hippocampus, basal ganglia, and midbrain of individuals clinically diagnosed with PSP and CTE. [17] [18] [19] [20] [21] 48, 49 However, we and others have noticed that this pattern, also observed in the three cases studied here, seems heavily influenced by the apparent nonspecific retention of this tracer in basal ganglia and off-target binding to neuromelanin-containing neurons in the substantia nigra 23 (Fig 1) . Other studies also suggest that this tracer has high affinity for monoamine oxidase (MAO)-A and MAO-B, enzymes abundantly present in the human brain, that might also contribute to its offtarget binding. 5, 50 Interestingly, although our PSP cases exhibited very robust tau pathology, for example, in the pallidus, thalamus, and rostral midbrain, where elevated in vivo [F-18]-AV-1451-PET retention was noticed, numerous tau inclusions were also present in cerebellum, limbic regions, and neocortex, where tracer signal was low. Similarly, in the MAPT P301L mutation carrier, the brain exam revealed predominant basal ganglia involvement, but abundant tau aggregates were also present in many other regions in cortex and white matter, where no elevated in vivo signal was noticed.
To date, only a few [F-18]-AV-1451 neuroimagingpathological single case reports have been published. [51] [52] [53] FIGURE 4: (A) Microphotographs from brain tissue slices stained with PHF-1 antibody (kind gift of Dr Peter Davis, left) and corresponding images displaying the optical threshold used to calculate tau burden using ImageJ software (NIH, right; representative images from subject 1, PSP: precentral cortex; subject 2, PSP: caudate; subject 3, MAPT P301L mutation carrier: putamen). (B) Correlation analysis between tau burden and in vivo [F-18]-AV-1451 PET uptake in matching ROIs. In subject 1, the highest tau burden was detected in basal ganglia (3.83%), frontal medial (2.92%), and precentral (2.46%) areas. In subject 2, the highest tau burden corresponded to basal ganglia (1.85%), dentate nucleus of the cerebellum (1.63%), and EC (1.77%). In subject 3, the highest load of tau grains was detected in superior frontal (4.22%), medial frontal (1.85%), and medial temporal areas ( In a R406W MAPT mutation carrier, antemortem [F-18]-AV-1451 retention correlated with postmortem distribution and semiquantitative measures of tau pathology. 51 Interestingly, this MAPT mutation is characterized by tau aggregates with PHF ultrastructure, 54 that contain all six isoforms of tau (3R and 4R) 46 resembling NFT found in AD. In two additional CBD cases, in vivo uptake correlated with tau immunostaining at postmortem. 52, 53 However, autoradiography was done only in one of them and showed minimal tracer binding. 52 To explore in depth the neuroimaging-pathological correlation in our three non-Alzheimer tauopathy cases, we analyzed the relationship of in vivo [F-18]-AV-1451-PET retention and in vitro [H-3]-AV-1451 binding in matched ROIs. We could not find a significant correlation between these measures in any of the cases. Similarly, our sensitive-autoradiography results showed no detectable binding of [F-18]-AV-1451 to brain regions with high tau burden, suggesting that most of the in vivo signal in medial temporal lobe and midbrain in these cases was likely driven by the presence of age-related tangles and off-target binding to neuromelanin-containing neurons in the substantia nigra, respectively, rather than by the 4R tau aggregates characteristic of these disorders. The underlying substrate for the [F-18]-AV-1451-PET retention in basal ganglia in these and other cases continues to be intriguing. Several groups, including our own, have noticed elevated basal ganglia in vivo signal in older adults regardless of the clinical diagnosis, including cognitively intact controls whose brains are not expected to harbor tau pathology in this region. [6] [7] [8] 12 This suggests that the in vivo PET signal in this region may represent, at least in part, nonspecific binding influenced by biological or technical factors that occur in vivo rather than underlying tau pathology. We cannot rule out with absolute certainty that the ethanol washing steps routinely used in autoradiography and in vitro binding assays to eliminate nonspecific binding may have removed some weaker AV-1451 labeling from basal ganglia. Importantly, quantification of tau burden in immunostained sections revealed no correlation between tau load at postmortem and [F-18]-AV-1541-PET retention in matching ROIs in any of the three cases. Further analysis of tau pools in ROIs by SDD-AGE allowed us to detect LMW-and HMW-tau aggregates and compare their amount to the corresponding [F-18]-AV-1541-PET uptake. No significant correlation was detected between these measurements in subjects 1 and 3. Only in subject 2 we detected a significant correlation between the observed in vivo signal and amounts of HMW total tau, HMW PHF-tau, and LMW PHF-tau. We interpret very cautiously these results because the significance in this case was driven by the basal ganglia; it was lost when this region was excluded from the analysis and could not be confirmed in the other 2 cases. Extrapolation of in vitro results to in vivo imaging findings always requires a very prudent interpretation, especially in the setting of demonstrated off-target binding and potential nonspecific retention.
In conclusion, the results from this study further favor the idea that tau tracer [F-18]-AV-1451 binds with high affinity to tau aggregates in the form of classic PHF-tau tangles containing all six isoforms of tau (including 3R and 4R) present in AD brains and as a function of age. However, they also indicate that this ligand exhibits relatively low binding affinity to tau inclusions predominantly made of 4R isoforms that adopt a structure of straight filaments, like those observed in the autopsy-confirmed PSP and MAPT P301L mutation cases presented here. These data suggest that this PET tau tracer may have a limited utility for the reliable detection of tau lesions in these nonAlzheimer tauopathies and highlight the need for further neuroimaging-pathological correlation studies to accurately interpret what in vivo [F-18]-AV-1451 PET positivity means.
